Calimmune
NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.
NEW YORK (GenomeWeb) – CalImmune this week announced that it has been cleared by the US Food and Drug Administration to treat a second cohort of patients in a clinical trial of its expressed RNAi-based treatment for HIV infection.
Calimmune has become the latest RNAi drug developer to move into the clinic, recently initiating a phase I/II trial of its HIV therapy Cal-1.
Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.
IP Update: Recent Patents, Patent Applications Awarded to Merck, Tekmira, CalImmune, and More
Premium
Title: Triggered RNAi
Patent Number: 8,241,854
Filed: May 22, 2009
Lead Inventor: Peng Yin, California Institute of Technology
Mar 15, 2012
Mar 8, 2012